Revance Therapeutics Total Assets 2012-2021 | RVNC

Revance Therapeutics total assets from 2012 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Revance Therapeutics Annual Total Assets
(Millions of US $)
2020 $720
2019 $340
2018 $226
2017 $296
2016 $204
2015 $276
2014 $192
2013 $23
2012 $13
2011 $40
Revance Therapeutics Quarterly Total Assets
(Millions of US $)
2021-09-30 $582
2021-06-30 $641
2021-03-31 $676
2020-12-31 $720
2020-09-30 $712
2020-06-30 $576
2020-03-31 $593
2019-12-31 $340
2019-09-30 $266
2019-06-30 $296
2019-03-31 $324
2018-12-31 $226
2018-09-30 $233
2018-06-30 $259
2018-03-31 $285
2017-12-31 $296
2017-09-30 $169
2017-06-30 $187
2017-03-31 $209
2016-12-31 $204
2016-09-30 $227
2016-06-30 $237
2016-03-31 $259
2015-12-31 $276
2015-09-30 $166
2015-06-30 $171
2015-03-31 $176
2014-12-31 $192
2014-09-30 $209
2014-06-30 $223
2014-03-31 $107
2013-12-31 $23
2013-09-30 $0
2013-06-30 $0
2013-03-31 $0
2012-12-31 $13
2011-12-31 $40
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.895B $0.015B
Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS? peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $121.281B 7.66
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.681B 21.48
Biohaven Pharmaceutical Holding (BHVN) United States $7.357B 0.00
Arcus Biosciences (RCUS) United States $3.170B 0.00
Emergent Biosolutions (EBS) United States $2.265B 8.14
Myovant Sciences (MYOV) United Kingdom $1.741B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.500B 0.00
Zymeworks (ZYME) Canada $0.902B 0.00
Ambrx Biopharma (AMAM) United States $0.391B 0.00
SQZ Biotechnologies (SQZ) United States $0.337B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.95